🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Recruitingn/aAges 15 Years - 90 YearsAllProteocyte Diagnostics Inc.
NCT04622462 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma Exclusion Criteria: * Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
💊

What it tests

  • Standard of Care Histopathology
  • STRATICYTE Assessment
📍

Where

3 sites
Kingsway Oral & Maxillofacial Surgery
Edmonton, Canada
University of Alberta
Edmonton, Canada
Western University
London, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy